Mechanisms of GZ17-6.02 resistance

Conclusions Our findings demonstrate that GZ17-6.02 has the potential to be developed as a colon cancer therapeutic and that resistance to the drug can be partially reversed by HDAC inhibitors.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Pre-Clinical Reports Source Type: research